Target Information
Target General Information | Top | |||||
---|---|---|---|---|---|---|
Target ID |
T08391
(Former ID: TTDC00187)
|
|||||
Target Name |
Janus kinase 2 (JAK-2)
|
|||||
Synonyms |
Tyrosine-protein kinase JAK2
|
|||||
Gene Name |
JAK2
|
|||||
Target Type |
Successful target
|
[1] | ||||
Disease | [+] 3 Target-related Diseases | + | ||||
1 | Myeloproliferative neoplasm [ICD-11: 2A20] | |||||
2 | Rheumatoid arthritis [ICD-11: FA20] | |||||
3 | Thrombocytosis [ICD-11: 3B63] | |||||
Function |
Mediates essential signaling events in both innate and adaptive immunity. In the cytoplasm, plays a pivotal role in signal transduction via its association with type I receptors such as growth hormone (GHR), prolactin (PRLR), leptin (LEPR), erythropoietin (EPOR), thrombopoietin (THPO); or type II receptors including IFN-alpha, IFN-beta, IFN-gamma and multiple interleukins. Following ligand-binding to cell surface receptors, phosphorylates specific tyrosine residues on the cytoplasmic tails of the receptor, creating docking sites for STATs proteins. Subsequently, phosphorylates the STATs proteins once they are recruited to the receptor. Phosphorylated STATs then form homodimer or heterodimers and translocate to the nucleus to activate gene transcription. For example, cell stimulation with erythropoietin (EPO) during erythropoiesis leads to JAK2 autophosphorylation, activation, and its association with erythropoietin receptor (EPOR) that becomes phosphorylated in its cytoplasmic domain. Then, STAT5 (STAT5A or STAT5B) is recruited, phosphorylated and activated by JAK2. Once activated, dimerized STAT5 translocates into the nucleus and promotes the transcription of several essential genes involved in the modulation of erythropoiesis. Part of a signaling cascade that is activated by increased cellular retinol and that leads to the activation of STAT5 (STAT5A or STAT5B). In addition, JAK2 mediates angiotensin-2-induced ARHGEF1 phosphorylation. Plays a role in cell cycle by phosphorylating CDKN1B. Cooperates with TEC through reciprocal phosphorylation to mediate cytokine-driven activation of FOS transcription. In the nucleus, plays a key role in chromatin by specifically mediating phosphorylation of 'Tyr-41' of histone H3 (H3Y41ph), a specific tag that promotes exclusion of CBX5 (HP1 alpha) from chromatin. Non-receptor tyrosine kinase involved in various processes such as cell growth, development, differentiation or histone modifications.
Click to Show/Hide
|
|||||
BioChemical Class |
Kinase
|
|||||
UniProt ID | ||||||
EC Number |
EC 2.7.10.2
|
|||||
Sequence |
MGMACLTMTEMEGTSTSSIYQNGDISGNANSMKQIDPVLQVYLYHSLGKSEADYLTFPSG
EYVAEEICIAASKACGITPVYHNMFALMSETERIWYPPNHVFHIDESTRHNVLYRIRFYF PRWYCSGSNRAYRHGISRGAEAPLLDDFVMSYLFAQWRHDFVHGWIKVPVTHETQEECLG MAVLDMMRIAKENDQTPLAIYNSISYKTFLPKCIRAKIQDYHILTRKRIRYRFRRFIQQF SQCKATARNLKLKYLINLETLQSAFYTEKFEVKEPGSGPSGEEIFATIIITGNGGIQWSR GKHKESETLTEQDLQLYCDFPNIIDVSIKQANQEGSNESRVVTIHKQDGKNLEIELSSLR EALSFVSLIDGYYRLTADAHHYLCKEVAPPAVLENIQSNCHGPISMDFAISKLKKAGNQT GLYVLRCSPKDFNKYFLTFAVERENVIEYKHCLITKNENEEYNLSGTKKNFSSLKDLLNC YQMETVRSDNIIFQFTKCCPPKPKDKSNLLVFRTNGVSDVPTSPTLQRPTHMNQMVFHKI RNEDLIFNESLGQGTFTKIFKGVRREVGDYGQLHETEVLLKVLDKAHRNYSESFFEAASM MSKLSHKHLVLNYGVCVCGDENILVQEFVKFGSLDTYLKKNKNCINILWKLEVAKQLAWA MHFLEENTLIHGNVCAKNILLIREEDRKTGNPPFIKLSDPGISITVLPKDILQERIPWVP PECIENPKNLNLATDKWSFGTTLWEICSGGDKPLSALDSQRKLQFYEDRHQLPAPKWAEL ANLINNCMDYEPDFRPSFRAIIRDLNSLFTPDYELLTENDMLPNMRIGALGFSGAFEDRD PTQFEERHLKFLQQLGKGNFGSVEMCRYDPLQDNTGEVVAVKKLQHSTEEHLRDFEREIE ILKSLQHDNIVKYKGVCYSAGRRNLKLIMEYLPYGSLRDYLQKHKERIDHIKLLQYTSQI CKGMEYLGTKRYIHRDLATRNILVENENRVKIGDFGLTKVLPQDKEYYKVKEPGESPIFW YAPESLTESKFSVASDVWSFGVVLYELFTYIEKSKSPPAEFMRMIGNDKQGQMIVFHLIE LLKNNGRLPRPDGCPDEIYMIMTECWNNNVNQRPSFRDLALRVDQIRDNMAG Click to Show/Hide
|
|||||
3D Structure | Click to Show 3D Structure of This Target | AlphaFold | ||||
ADReCS ID | BADD_A03237 | |||||
HIT2.0 ID | T65S3S |
Drugs and Modes of Action | Top | |||||
---|---|---|---|---|---|---|
Approved Drug(s) | [+] 3 Approved Drugs | + | ||||
1 | Baricitinib | Drug Info | Approved | Rheumatoid arthritis | [2] | |
2 | Fedratinib | Drug Info | Approved | Myelofibrosis | [3] | |
3 | Ruxolitinib | Drug Info | Approved | High-risk myelofibrosis | [4], [5], [6], [7] | |
Clinical Trial Drug(s) | [+] 15 Clinical Trial Drugs | + | ||||
1 | ITF2357 | Drug Info | Phase 3 | Duchenne dystrophy | [8] | |
2 | Momelotinib | Drug Info | Phase 3 | Myelofibrosis | [9], [10], [11] | |
3 | Pacritinib | Drug Info | Phase 3 | Myelofibrosis | [12], [13], [14], [15] | |
4 | XL019 | Drug Info | Phase 3 | Solid tumour/cancer | [16], [17] | |
5 | AZD1480 | Drug Info | Phase 2 | Myeloproliferative syndrome | [18], [19] | |
6 | BMS-911543 | Drug Info | Phase 2 | Myelofibrosis | [20], [21] | |
7 | Cerdulatinib | Drug Info | Phase 2 | B-cell lymphoma | [15] | |
8 | CTP-543 | Drug Info | Phase 2 | Asthma | [22], [23] | |
9 | CTP-543 | Drug Info | Phase 2 | Alopecia | [24] | |
10 | INCB039110 | Drug Info | Phase 2 | Malignant neoplasm | [25] | |
11 | LY2784544 | Drug Info | Phase 2 | Breast cancer | [26], [27], [28] | |
12 | NS-018 | Drug Info | Phase 1/2 | Myelofibrosis | [29], [30], [15] | |
13 | AC430 | Drug Info | Phase 1 | leukaemia | [31] | |
14 | Peginterferon beta | Drug Info | Phase 1 | Multiple sclerosis | [32] | |
15 | SB-1578 | Drug Info | Phase 1 | Solid tumour/cancer | [33] | |
Discontinued Drug(s) | [+] 1 Discontinued Drugs | + | ||||
1 | AG490 | Drug Info | Terminated | Multiple myeloma | [34], [35] | |
Mode of Action | [+] 2 Modes of Action | + | ||||
Modulator | [+] 10 Modulator drugs | + | ||||
1 | Baricitinib | Drug Info | [36] | |||
2 | Ruxolitinib | Drug Info | [1] | |||
3 | Momelotinib | Drug Info | [39], [40] | |||
4 | Pacritinib | Drug Info | [41] | |||
5 | AZD1480 | Drug Info | [42] | |||
6 | BMS-911543 | Drug Info | [21] | |||
7 | Cerdulatinib | Drug Info | [43] | |||
8 | LY2784544 | Drug Info | [46] | |||
9 | NS-018 | Drug Info | [30] | |||
10 | AC430 | Drug Info | [36] | |||
Inhibitor | [+] 99 Inhibitor drugs | + | ||||
1 | Fedratinib | Drug Info | [3] | |||
2 | ITF2357 | Drug Info | [37], [38] | |||
3 | XL019 | Drug Info | [37] | |||
4 | CTP-543 | Drug Info | [22] | |||
5 | CTP-543 | Drug Info | [44] | |||
6 | INCB039110 | Drug Info | [45] | |||
7 | Peginterferon beta | Drug Info | [47] | |||
8 | SB-1578 | Drug Info | [36], [48] | |||
9 | 1,2,4-triazolo[1,5a]pyridine derivative 1 | Drug Info | [49] | |||
10 | 1,2,4-triazolo[1,5a]pyridine derivative 2 | Drug Info | [49] | |||
11 | Alkynyl-substituted pyrimidinyl-pyrrole derivative 1 | Drug Info | [50] | |||
12 | Aminooxazole carboxamide derivative 1 | Drug Info | [50] | |||
13 | Aminotriazolopyridine derivative 1 | Drug Info | [49] | |||
14 | Aromatic bicyclic compound 1 | Drug Info | [51] | |||
15 | Aromatic bicyclic compound 2 | Drug Info | [51] | |||
16 | Aromatic bicyclic compound 3 | Drug Info | [51] | |||
17 | Aromatic bicyclic compound 4 | Drug Info | [51] | |||
18 | Aromatic bicyclic compound 5 | Drug Info | [51] | |||
19 | Aromatic bicyclic compound 6 | Drug Info | [51] | |||
20 | Benzimidazole derivative 7 | Drug Info | [49] | |||
21 | Bis-aminopyrimidine derivative 1 | Drug Info | [49] | |||
22 | Bis-aminopyrimidine derivative 2 | Drug Info | [49] | |||
23 | Bis-aminopyrimidine derivative 3 | Drug Info | [49] | |||
24 | Bis-aminopyrimidine derivative 4 | Drug Info | [49] | |||
25 | Bis-aminopyrimidine derivative 5 | Drug Info | [49] | |||
26 | Curcumin analog 1 | Drug Info | [51] | |||
27 | Curcumin analog 2 | Drug Info | [51] | |||
28 | Cyanomethyl pypazole carboxamide derivative 1 | Drug Info | [50] | |||
29 | Cyclic cyanoethypypazole derivative 1 | Drug Info | [50] | |||
30 | Cycloalkyl nitrile pyrazole carboxamide derivative 1 | Drug Info | [50] | |||
31 | Cycloalkyl nitrile pyrazolo pyridone derivative 1 | Drug Info | [50] | |||
32 | Cycloalkyl nitrile pyrazolo pyridone derivative 2 | Drug Info | [50] | |||
33 | Five-and-six-membered heterocyclic compound 1 | Drug Info | [50] | |||
34 | Geminally-substituted cyanoethylpypazolo pyridone derivative 1 | Drug Info | [50] | |||
35 | Geminally-substituted cyanoethylpypazolo pyridone derivative 2 | Drug Info | [50] | |||
36 | Imidazo[4,5-c]pyridine derivative 2 | Drug Info | [49] | |||
37 | Isoxazole derivative 1 | Drug Info | [50] | |||
38 | Isoxazole derivative 2 | Drug Info | [50] | |||
39 | N-(cyanomethyl)-4-(2-(phenylamino)pyrimidin-4-yl)benzamide derivative 1 | Drug Info | [49] | |||
40 | PMID27774822-Compound-Figure10Compound12 | Drug Info | [50] | |||
41 | PMID27774822-Compound-Figure10Compound4 | Drug Info | [50] | |||
42 | PMID27774822-Compound-Figure10Example1 | Drug Info | [50] | |||
43 | PMID27774822-Compound-Figure10Example19 | Drug Info | [50] | |||
44 | PMID27774822-Compound-Figure11Example5 | Drug Info | [50] | |||
45 | PMID27774822-Compound-Figure1Example20 | Drug Info | [50] | |||
46 | PMID27774822-Compound-Figure2Example1-1left | Drug Info | [50] | |||
47 | PMID27774822-Compound-Figure2Example1-1right | Drug Info | [50] | |||
48 | PMID27774822-Compound-Figure3CompoundI-165 | Drug Info | [50] | |||
49 | PMID27774822-Compound-Figure7Example63 | Drug Info | [50] | |||
50 | PMID27774822-Compound-Figure8Example5 | Drug Info | [50] | |||
51 | PMID27774824-Compound-Figure11Example1up | Drug Info | [49] | |||
52 | PMID27774824-Compound-Figure2Example4 | Drug Info | [49] | |||
53 | PMID27774824-Compound-Figure3Example18 | Drug Info | [49] | |||
54 | PMID27774824-Compound-Figure6Example12 | Drug Info | [49] | |||
55 | PMID27774824-Compound-Figure6Example6 | Drug Info | [49] | |||
56 | PMID27774824-Compound-Figure7Example10 | Drug Info | [49] | |||
57 | PMID27774824-Compound-Figure8Example22 | Drug Info | [49] | |||
58 | PMID27774824-Compound-Figure8Example99 | Drug Info | [49] | |||
59 | PMID27774824-Compound-Figure9Example2down | Drug Info | [49] | |||
60 | PMID27774824-Compound-Figure9Example2up | Drug Info | [49] | |||
61 | Pyrazolopyridine derivative 3 | Drug Info | [50] | |||
62 | Pyrazolopyridine derivative 4 | Drug Info | [50] | |||
63 | Pyrazolopyridine derivative 6 | Drug Info | [49] | |||
64 | Pyrazolopyridine derivative 7 | Drug Info | [49] | |||
65 | Pyrazolo[4,3-c]pyridine derivative 2 | Drug Info | [49] | |||
66 | Pyrimidopyridazinone derivative 1 | Drug Info | [49] | |||
67 | Pyrimidopyridazinone derivative 2 | Drug Info | [49] | |||
68 | Pyrrole derivative 7 | Drug Info | [50] | |||
69 | Pyrrole six-membered heteroaryl ring derivative 1 | Drug Info | [50] | |||
70 | Pyrrolo-pyridine derivative 3 | Drug Info | [50] | |||
71 | Pyrrolo-pyridone derivative 1 | Drug Info | [50] | |||
72 | Pyrrolo-pyridone derivative 2 | Drug Info | [50] | |||
73 | Pyrrolo[2,3-d]pyrimidine derivative 11 | Drug Info | [49] | |||
74 | Pyrrolo[2,3-d]pyrimidine derivative 6 | Drug Info | [50] | |||
75 | Pyrrolo[2,3-d]pyrimidine derivative 7 | Drug Info | [50] | |||
76 | Pyrrolo[2,3-d]pyrimidine derivative 8 | Drug Info | [50] | |||
77 | Ruxolitinib derivative 2 | Drug Info | [49] | |||
78 | Triazolo-pyridine derivative 1 | Drug Info | [50] | |||
79 | Tricyclic compound 1 | Drug Info | [49] | |||
80 | Tricyclic compound 11 | Drug Info | [50] | |||
81 | Tricyclic heterocycle derivative 1 | Drug Info | [50] | |||
82 | Tricyclic heterocycle derivative 2 | Drug Info | [49] | |||
83 | Tricyclic heterocycle derivative 5 | Drug Info | [50] | |||
84 | Tricyclic pyrrolopyridine compound 1 | Drug Info | [50] | |||
85 | AG490 | Drug Info | [52], [53] | |||
86 | 1,2,3,4,5,6-hexabromocyclohexane | Drug Info | [54] | |||
87 | 5-phenyl-1H-indazol-3-amine | Drug Info | [55] | |||
88 | AMG-JAK2-01 | Drug Info | [45] | |||
89 | Atropisomer 1 | Drug Info | [56] | |||
90 | AZ960 | Drug Info | [57] | |||
91 | BVB-808 | Drug Info | [45] | |||
92 | CMP-6 | Drug Info | [58] | |||
93 | K-454 | Drug Info | [45] | |||
94 | NSC-1771 | Drug Info | [59] | |||
95 | ON-044580 | Drug Info | [60] | |||
96 | PMID21493067C1d | Drug Info | [61] | |||
97 | PMID24359159C19a | Drug Info | [62] | |||
98 | SGI-1252 | Drug Info | [45] | |||
99 | WHI-P154 | Drug Info | [63] |
Chemical Structure based Activity Landscape of Target | Top |
---|---|
Drug Property Profile of Target | Top | |
---|---|---|
(1) Molecular Weight (mw) based Drug Clustering | (2) Octanol/Water Partition Coefficient (xlogp) based Drug Clustering | |
|
||
(3) Hydrogen Bond Donor Count (hbonddonor) based Drug Clustering | (4) Hydrogen Bond Acceptor Count (hbondacc) based Drug Clustering | |
|
||
(5) Rotatable Bond Count (rotbonds) based Drug Clustering | (6) Topological Polar Surface Area (polararea) based Drug Clustering | |
|
||
"RO5" indicates the cutoff set by lipinski's rule of five; "D123AB" colored in GREEN denotes the no violation of any cutoff in lipinski's rule of five; "D123AB" colored in PURPLE refers to the violation of only one cutoff in lipinski's rule of five; "D123AB" colored in BLACK represents the violation of more than one cutoffs in lipinski's rule of five |
Co-Targets | Top | |||||
---|---|---|---|---|---|---|
Co-Targets |
Target Poor or Non Binders | Top | |||||
---|---|---|---|---|---|---|
Target Poor or Non Binders |
Target Regulators | Top | |||||
---|---|---|---|---|---|---|
Target-regulating microRNAs | ||||||
Target-interacting Proteins |
Target Profiles in Patients | Top | |||||
---|---|---|---|---|---|---|
Target Expression Profile (TEP) | ||||||
Drug Resistance Mutation (DRM) |
Target-Related Models and Studies | Top | |||||
---|---|---|---|---|---|---|
Target Validation |
References | Top | |||||
---|---|---|---|---|---|---|
REF 1 | 2011 FDA drug approvals. Nat Rev Drug Discov. 2012 Feb 1;11(2):91-4. | |||||
REF 2 | 2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89. | |||||
REF 3 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019 | |||||
REF 4 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5688). | |||||
REF 5 | ClinicalTrials.gov (NCT02038036) Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy.. U.S. National Institutes of Health. | |||||
REF 6 | Ruxolitinib versus standard therapy for the treatment of polycythemia vera. N Engl J Med. 2015 Jan 29;372(5):426-35. | |||||
REF 7 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. | |||||
REF 8 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 9 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7791). | |||||
REF 10 | ClinicalTrials.gov (NCT01969838) Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis. U.S. National Institutes of Health. | |||||
REF 11 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 12 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7793). | |||||
REF 13 | Clinical pipeline report, company report or official report of CTI BioPharma. | |||||
REF 14 | ClinicalTrials.gov (NCT02055781) Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia. U.S. National Institutes of Health. | |||||
REF 15 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 16 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7971). | |||||
REF 17 | Update on JAK2 Inhibitors in Myeloproliferative Neoplasm. Ther Adv Hematol. 2011 Apr;2(2):61-71. | |||||
REF 18 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5933). | |||||
REF 19 | The Janus kinases inhibitor AZD1480 attenuates growth of small cell lung cancers in vitro and in vivo. Clin Cancer Res. 2013 Dec 15;19(24):6777-86. | |||||
REF 20 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7954). | |||||
REF 21 | Characterization of BMS-911543, a functionally selective small-molecule inhibitor of JAK2. Leukemia. 2012 Feb;26(2):280-8. | |||||
REF 22 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 23 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||||
REF 24 | ClinicalTrials.gov (NCT03898479) Extension Study to Evaluate Safety and Efficacy of CTP-543 in Adults With Alopecia Areata. U.S. National Institutes of Health. | |||||
REF 25 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8364). | |||||
REF 26 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7909). | |||||
REF 27 | ClinicalTrials.gov (NCT01594723) A Study of LY2784544 in Participants With Myeloproliferative Neoplasms. U.S. National Institutes of Health. | |||||
REF 28 | LY2784544, a small molecule JAK2 inhibitor, induces apoptosis in inflammatory breast cancer spheres through targeting IL-6-JAK-STAT3 pathway. Cancer Research 07/2011; 71(8 Supplement):2820-2820. | |||||
REF 29 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7839). | |||||
REF 30 | Effect of NS-018, a selective JAK2V617F inhibitor, in a murine model of myelofibrosis. Blood Cancer J. 2014 Jan 10;4:e174. | |||||
REF 31 | ClinicalTrials.gov (NCT01287858) Study to Assess Safety, Tolerability, and Pharmacokinetics of Oral Doses for AC430 in Healthy Subjects. U.S. National Institutes of Health. | |||||
REF 32 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032732) | |||||
REF 33 | ClinicalTrials.gov (NCT01235871) A Single and Multiple-Dose Study of SB1578. U.S. National Institutes of Health. | |||||
REF 34 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5916). | |||||
REF 35 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800006610) | |||||
REF 36 | Selective JAK inhibitors in development for rheumatoid arthritis. Expert Opin Investig Drugs. 2014 Aug;23(8):1067-77. | |||||
REF 37 | Emerging drugs for the therapy of primary and post essential thrombocythemia, post polycythemia vera myelofibrosis. Expert Opin Emerg Drugs. 2009 Sep;14(3):471-9. | |||||
REF 38 | Emerging therapies for multiple myeloma. Expert Opin Emerg Drugs. 2009 Mar;14(1):99-127. | |||||
REF 39 | Genetic determinants of response and survival in momelotinib-treated patients with myelofibrosis.Leukemia.2015 Mar;29(3):741-4. | |||||
REF 40 | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.Blood.2010 Jun 24;115(25):5232-40. | |||||
REF 41 | National Cancer Institute Drug Dictionary (drug id 609888). | |||||
REF 42 | The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell. 2009 Dec 8;16(6):487-97. | |||||
REF 43 | Company report (Portola Pharmaceuticals) | |||||
REF 44 | Clinical pipeline report, company report or official report of Concert Pharmaceuticals. | |||||
REF 45 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2048). | |||||
REF 46 | Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J. 2013 Apr 12;3:e109. | |||||
REF 47 | Comparison of mutated ABL1 and JAK2 as oncogenes and drug targets in myeloproliferative disorders. Leukemia. 2008 Jul;22(7):1320-34. | |||||
REF 48 | SB1578, a novel inhibitor of JAK2, FLT3, and c-Fms for the treatment of rheumatoid arthritis. J Immunol. 2012 Oct 15;189(8):4123-34. | |||||
REF 49 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 1.Expert Opin Ther Pat. 2017 Feb;27(2):127-143. | |||||
REF 50 | Inhibitors of JAK-family kinases: an update on the patent literature 2013-2015, part 2.Expert Opin Ther Pat. 2017 Feb;27(2):145-161. | |||||
REF 51 | A STAT inhibitor patent review: progress since 2011.Expert Opin Ther Pat. 2015;25(12):1397-421. | |||||
REF 52 | Jak2 tyrosine kinase mediates oxidative stress-induced apoptosis in vascular smooth muscle cells. J Biol Chem. 2004 Aug 13;279(33):34547-52. | |||||
REF 53 | The JAK2 inhibitor AG490 predominantly abrogates the growth of human B-precursor leukemic cells with 11q23 translocation or Philadelphia chromosome. Leukemia. 2001 Nov;15(11):1758-68. | |||||
REF 54 | Identification of 1,2,3,4,5,6-hexabromocyclohexane as a small molecule inhibitor of jak2 tyrosine kinase autophosphorylation [correction of autophophorylation]. J Med Chem. 2005 Apr 7;48(7):2526-33. | |||||
REF 55 | The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. | |||||
REF 56 | Janus kinase 2 inhibitors. Synthesis and characterization of a novel polycyclic azaindole. J Med Chem. 2009 Dec 24;52(24):7938-41. | |||||
REF 57 | Effects of the JAK2 inhibitor, AZ960, on Pim/BAD/BCL-xL survival signaling in the human JAK2 V617F cell line SET-2. J Biol Chem. 2008 Nov 21;283(47):32334-43. | |||||
REF 58 | Photochemical preparation of a pyridone containing tetracycle: a Jak protein kinase inhibitor. Bioorg Med Chem Lett. 2002 Apr 22;12(8):1219-23. | |||||
REF 59 | In silico identification and biochemical evaluation of novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2). Bioorg Med Chem Lett. 2010 Dec 15;20(24):7331-6. | |||||
REF 60 | A Non-ATP-Competitive Dual Inhibitor of JAK2 and BCR-ABL Kinases: Elucidation of a Novel Therapeutic Spectrum Based on Substrate Competitive Inhibition. Genes Cancer. 2010 Apr;1(4):331-45. | |||||
REF 61 | In vitro and in vivo evaluation of 6-aminopyrazolyl-pyridine-3-carbonitriles as JAK2 kinase inhibitors. Bioorg Med Chem Lett. 2011 May 15;21(10):2958-61. | |||||
REF 62 | Discovery of 1-methyl-1H-imidazole derivatives as potent Jak2 inhibitors. J Med Chem. 2014 Jan 9;57(1):144-58. | |||||
REF 63 | The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.